<DOC>
	<DOC>NCT01593527</DOC>
	<brief_summary>The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult to treat gouty arthritis and moderate to severe CKD (stage 3 - 4).</brief_summary>
	<brief_title>Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Arthritis, Gouty</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Confirmed diagnosis of gouty arthritis History of ≥ 3 gouty arthritis flares within the previous 12 months Confirmed diagnosis/ documented history of chronic kidney disease (CKD) Stages 3or4 Onset of current acute gouty arthritis flare within 3 days prior to randomization Exclusion criteria: Hemodialysis CKD Stage 5 Organ transplantation Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis Live vaccinations within 3 months prior to randomization Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Frequent flares</keyword>
	<keyword>Frequent attacks</keyword>
	<keyword>gout</keyword>
	<keyword>gouty arthritis</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>renal impairment</keyword>
	<keyword>Anti-interleukin-1β monoclonal antibody</keyword>
	<keyword>anti-inflammatory therapy</keyword>
</DOC>